187 related articles for article (PubMed ID: 31797196)
1. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
[TBL] [Abstract][Full Text] [Related]
2. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.
Shi JH; Luo L; Chen XL; Pan YP; Zhang Z; Fang H; Chen Y; Chen WD; Cao Q
World J Gastroenterol; 2020 Nov; 26(41):6455-6474. PubMed ID: 33244205
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
4. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ; Stevens TW; Eshuis EJ; Gardenbroek TJ; Bosmans JE; van Dongen JM; Mol B; Buskens CJ; Stokkers PCF; Hart A; D'Haens GR; Bemelman WA; Ponsioen CY;
Gut; 2019 Oct; 68(10):1774-1780. PubMed ID: 31233395
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
Punekar YS; Sunderland T; Hawkins N; Lindsay J
Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
[TBL] [Abstract][Full Text] [Related]
8. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
[TBL] [Abstract][Full Text] [Related]
9. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
Catt H; Bodger K; Kirkham JJ; Hughes DA
Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
12. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
Vasudevan A; Ip F; Liew D; van Langenberg DR
Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
[TBL] [Abstract][Full Text] [Related]
14. Management for severe Crohn's disease: a lifetime cost-utility analysis.
Jaisson-Hot I; Flourié B; Descos L; Colin C
Int J Technol Assess Health Care; 2004; 20(3):274-9. PubMed ID: 15446756
[TBL] [Abstract][Full Text] [Related]
15. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
Bolin K; Hertervig E; Louis E
J Crohns Colitis; 2019 Sep; 13(10):1323-1333. PubMed ID: 30893421
[TBL] [Abstract][Full Text] [Related]
16. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
